Research Article
Progressive Improvement in 5-Year Survival Rates for Extremity Soft Tissue Sarcomas from 1999 to 2019
Table 2
Univariate 5-year survival analysis stratified by time period.
| Variable | 1999–2005 (n = 1,393) | 2006–2012 (n = 2,074) | 2013–2019 (n = 2,187) | Survival (%) | | Survival (%) | | Survival (%) | |
| Demographics | Sex | Male | 45 | 0.136 | 60 | 0.249 | 76 | 0.057 | Female | 50 | 62 | 79 | Age group (years) | <30 | 78 | <0.001 | 72 | <0.001 | 89 | <0.001 | 30–59 | 62 | 73 | 84 | ≥60 | 25 | 48 | 71 | Race | Caucasian | 47 | 0.342 | 62 | 0.257 | 78 | 0.173 | African American | 43 | 57 | 72 | Other | 48 | 59 | 79 | Unknown | 88 | 86 | 83 | Ethnicity | Non-Hispanic | 46 | 0.008 | 60 | 0.056 | 77 | 0.126 | Hispanic | 58 | 67 | 81 | Marital status | Married | 49 | <0.001 | 65 | <0.001 | 81 | <0.001 | Single | 55 | 62 | 79 | Other | 32 | 46 | 64 | Unknown | 67 | 62 | 82 |
| Tumor characteristics | Primary site | Upper extremity | 54 | 0.151 | 61 | 0.185 | 76 | 0.226 | Lower extremity | 45 | 61 | 78 | Size (cm) | <5 | 60 | <0.001 | 73 | <0.001 | 89 | <0.001 | 5–10 | 47 | 60 | 79 | >10 | 37 | 52.2 | 68 | Grade | I | 65 | <0.001 | 87 | <0.001 | 93 | <0.001 | II | 61 | 74 | 86 | III | 36 | 47 | 68 | Metastasis | No | 53 | <0.001 | 68 | <0.001 | 82 | <0.001 | Yes | 33 | 43 | 49 | Histology | Fibromatous | 41 | <0.001 | 60 | <0.001 | 81 | <0.001 | Myxomatous | 46 | 69 | 81 | Lipomatous | 60 | 78 | 89 | Myomatous | 43 | 53 | 72 | Synovial | 54 | 62 | 81 | NOS | 38 | 44 | 58 | All other types | 38 | 47 | 70 |
| Treatments | Surgery | No | 21 | <0.001 | 14 | <0.001 | 35 | <0.001 | Yes | 48 | 63 | 81 | Radiation | No/unknown | 48 | 0.731 | 65 | 0.005 | 78 | 0.333 | Yes | 47 | 58 | 77 | Chemotherapy | No/unknown | 49 | 0.011 | 66 | <0.001 | 81 | <0.001 | Yes | 40 | 45 | 62 | Overall survival (%) | 47 | 61 | 78 |
|
|
NOS, not otherwise specified; significant values are in bold.
|